Ellagic acid: Cytodifferentiating and antiproliferative effects in human prostatic cancer cell lines

Current Pharmaceutical Design

Volumn 19, Issue 15, 2013, Pages 2728-2736

  Vanella, Luca ^a   Barbagallo, Ignazio ^a   Acquaviva, Rosaria ^a   Di Giacomo, Claudia ^a   Cardile, Venera ^a   Abraham, Nader G ^b   Sorrenti, Valeria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cytodifferentiation; Ellagic acid; Prostate cancer

Indexed keywords

CHROMOGRANIN A; DNA; DNA METHYLTRANSFERASE 1; ELLAGIC ACID; NEUROTROPHIN RECEPTOR P75; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRAIN LNCAP; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOGRANIN A; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ELLAGIC ACID; HUMANS; L-LACTATE DEHYDROGENASE; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NERVE GROWTH FACTOR; RETINOBLASTOMA PROTEIN;

EID: 84876728812     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319150008     Document Type: Article

References (72)

1. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60: 5857-61.
2. Bostwick DG, Grignon DJ, Hammond ME et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 995-1000.
3. Ross JS, Sheehan CE, Dolen EM, Kallakury BV. Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002; 9: 115-28.
4. Veltri RW, O'Dowd GJ, Orozco R, Miller MC. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. Semin Urol Oncol 1998; 16: 106-17.
5. Imamoto T, Suzuki H, Akakura K, et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001; 48: 573-78.
6. Komiya A, Suzuki H, Ueda T, et al. Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer. Genes Chromosomes Cancer 1996; 17: 245-53.
7. JT Arnoldl and J T Isaacs Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocrine-Related Cancer, 2002; 9: 61-73.
8. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6.
9. Berruti A, Dogliotti L, Mosca A, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590-97.
10. Angelsen A, Syversen U, Stridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997; 31: 110-7.
11. Kamiya N, Akakura K, Suzuki H Isshiki S, Komiya A, Ueda T, Ito H. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003; 44: 309-14; discussion 314.
12. Kamiya N, Suzuki H, Kawamura K et al. Neuroendocrine differentiation in stage D2 prostate cancers. Int. J. Urol. 2008; 15: 423-28.
13. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512-5.
14. Cussenot O, Villette JM, Valeri A Cariou G, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155: 1340-43.
15. Lilleby W, Paus E, Skovlund E, Fossa SD. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001; 46: 126-33.
16. Tarle M, Frkovic-Grazio S, Kraljic I, Kovacic K. A more objective staging of advanced prostate cancer-routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate 1994; 24: 143-48.
17. Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146: 358-61.
18. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate Suppl 1998; 8: 43-51.
19. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-48.
20. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503-19.
21. di Sant'Agnese P.A. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann of Oncol 2001; 12 (Suppl.2): S135-S140.
22. Hirano D, Jike T, Okada Y, et al. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the Prostate: an immunoelectron microscopic study. Ultrastruct Pathol 2005; 29: 367-75.
23. Krijnen JL, Bogdanowicz J, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158: 171-4.
24. Paul AB, Grant ES, Habib FK. The expression and localization of β-nerve growth factor (β-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation. Br J Cancer 1996; 74: 1990-96.
25. Montano X, Djamgoz MBA. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 2004; 571: 1-8.
26. Pflug BR, Onoda M, Lynch JH, Djakiew D. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992; 52: 5403-6.
27. Kang NJ, Shin SH, Lee HJ, Lee KW. Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis. Pharmacol & Therap 2011; 130: 310-24.
28. Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: Phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev 2012; 38: 76-87.
29. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J Agric Food Chem 2000; 48: 4581-9.
30. Aviram M, Dornfield L, Rosenblatt M, et al. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 2000; 71: 1062-76.
31. Kaplan M, Hayek T, Raz A, Coleman R, Dornfield L, Vaya J, Aviram M. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001; 131: 2082-9.
32. Kim ND, Mehta R, Yu W, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203-17.
33. Cerda B, Ceron JJ, Tomas-Barberan FA, Espin JC. Repeated oral administration of high doses of pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem 2003; 51: 3493-501.
34. Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 2003; 42: 18-28.
35. Narayanan BA, Geoffrey O, Willingham MC, Re GG, Nixon DW. p53/p21 (WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Lett 1999; 136: 215-21.
36. Khanduja KL, Gandhi RK, Pathania V, Syanl N. Prevention of Nnitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. Food Chem Toxicol 1999; 37: 313-8.
37. Mertens-Talcott SU, Talcott ST, Percival SS. Low concentrations of quercetin and ellagic acid synergistically influence proliferation, cytotoxicity and apoptosis in MOLT-4 human leukemia cells. J Nutr 2003; 133: 2669-74.
38. Heber D. Multitargeted therapy of cancer by ellagitannins Cancer Lett 2008; 269: 262-8.
39. Seeram NP, Adams T, Henning SM, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J of Nutr Biochem 2005; 16: 360-7.
40. Seeram NP, Aronson WJ, Zhang Y, et al. Pomegranate Ellagitannin-Derived Metabolites Inhibit Prostate Cancer Growth and Localize to the Mouse Prostate Gland. J Agric Food Chem 2007; 55: 7732-7.
41. Falsaperla M, Morgia G, Tartarone A, Ardito R, Romano G. Support Ellagic Acid Therapy in Patients with Hormone Refractory Prostate Cancer (HRPC) on Standard Chemotherapy Using Vinorelbine and Estramustine Phosphate. Eur Urol 2005; 47: 449-55.
42. Lansky EP, Harrison G, Froom P, Jiang WG. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel TM. Invest New Drugs 2005; 23: 121-2.
43. Sartippour M, Seeram NP, Rao JY, et al. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo Int J Oncol 2008; 32: 475-80.
44. Garattini E, Gianni' M, Terao M. Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm. 2007; 75: 301-54.
45. Serafino A, Sinibaldi-Vallebona P, Lazzarino G, et al. Differentiation of human melanoma cells induced by cyanidin-3-O-β-glucopyranoside. Faseb J 2004; 18: 1940-2.
46. Vanella L, Di Giacomo C, Acquaviva R, et al. The DDAH/NOS pathway in human prostatic cancer cell lines: antiangiogenic effect of L-NAME. Int J Oncol. 2011; 39: 1303-10.
47. Sigala S, Tognazzi N, Rizzetti MC, et al. Nerve growth factor induces the re-expression of functional androgen receptors and p75NGFR in the androgen-insensitive prostate cancer cell line DU145. Eur J Endocrinol 2002; 147: 407-15.
48. Vivanco I, Sawyers CL. The phosphatidylinositol 3 Kinase Akt pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
49. Singh NP, Muller CH, Berger RE. Effects of age on DNA doublestrandbreaks and apoptosis in human sperm. Fertil Steril 2003; 80: 1420-30.
50. Cardile V, Scifo C, Russo A, Falsaperla M, Morgia G, Motta M, Renis M, Imbriani E, Silvestre G. Involvement of HSP70 in resveratrol-induced apoptosis of human prostate cancer. Anticancer Res 2003; 23: 4921-26.
51. Russo A, Cardile V, Lombardo L, Vanella L, Acquaviva R. Genistin inhibits UV light-induced plasmid DNA damage and cell growth in human melanoma cells. J Nutr Biochem 2006; 17: 103-8.
52. 2 cells with anthocyanins. Br J Nutr 2008; 27-35
53. Pflug BR, Djakiew D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor induced cell growth by activation of programmed cell death. Mol Carcinogen 1998; 23: 106-14.
54. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001; 10: 699-703.
55. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression, Cancer Res 2000; 60: 6111-15.
56. Wang Y, Hayward SW, Donjacour AA, et al. Sex hormoneinduced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000; 60: 6008-17.
57. Lin J, Haffner MC, Zhang Y, et al. Disulfiram Is a DNA Demethylating Agent and Inhibits Prostate Cancer Cell Growth. Prostate 2011; 71: 333-43.
58. McCabe MT, Davis JN and Day ML. Regulation of DNA Methyltransferase 1 by the pRb/E2F1 Pathway. Cancer Res 2005; 65: 3624-32.
59. Ruiz-Magaña MJ, Rodríguez-Vargas JM, Morales JC, Saldivia MA, Schulze-Osthoff K, Ruiz-Ruiz C. The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells. Int J Cancer 2012; 130: 1195-207.
60. Aruoma OI. Antioxidant actions of plant foods. Use of oxidative DNA damage as a tool for studying antioxidant efficacy. Free Radic Res 1999; 30: 419-27.
61. Grether ME, Abrams JM, Agapite J, White K, Steller H. The head involution defective gene of Drosophila melanogaster functions in programmed cell death. Genes Dev 1995; 9: 1694-708.
62. Clarke RB. p27KIP1 phosphorylation by PKB/Akt leads to poor breast cancer prognosis. Breast Cancer Res 2003; 5: 162-3.
63. Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 17: 590-603.
64. Li Y, Sarkar FH. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 2002; 8: 2369-77.
65. Chinni SR, Sarkar FH. Akt inactivation is a key event indole-3-carbinol-induced apoptosis in PC-3 cells. Clin Cancer Res 2002; 8: 1228-36.
66. Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation throught he downregulation of Akt, IkappaB kinase activation and NF-kappaB-regulated gene expression. Oncogene 2006; 25: 1463-73.
67. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, ShishodiaS, Aggarwal BB. Curcumin (diferuloylmethane) downregulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation. Mol Pharmacol 2006; 69: 195-206.
68. Tang FY, Nguyen N, Meydani M. Green tea catechins inhibit VEGF-induced angiogenesis in vitro through suppression of VEcadherin phosphorylation and inactivation of Akt molecule. Int J Cancer 2003; 106: 871-8.
69. Huang C, Li J, Song L, et al. Black raspberry extracts inhibit benzo(a)pyrenediol-epoxide-induced activator protein 1 activation and VEGF transcription by targeting the phosphotidylinositol 3-kinase/Akt pathway. Cancer Res 2006; 66: 581-7.
70. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. J Cell Biochem 2003; 89: 1-5.
71. Losso JN, Bansode RR, Trappey A 2nd, Bawadi HA, Truax R. In vitro anti-proliferative activities of ellagic acid. J Nutr. Biochem. 2004; 15: 672-8.
72. Bhosle SM, Huilgol NG, Mishra KP. Enhancement of radiationinduced oxidative stress and cytotoxicity in tumor cells by ellagic acid. Clin Chim Acta 2005; 359: 89-100.